...Carmelo Boccafoschi; Mansueto Montefiore; Massimo Pastormerlo; Scipio Annoscia; Cristina Lozzi; Pier-Giacomo Betta The lymphocytes infiltrating the bladder mucosa of 28 patients treated with bacillus Calmette-Guérin (BCG) for superficial bladder carcinoma were characterized using...

...J.A. Martínez-Piñeiro; P. Muntañola The therapeutic and prophylactic value of nonspecific immunological stimulation with BCG vaccine against papillary bladder carcinomas has been evaluated. Nine patients were treated and followed for periods of 4—9 months. Attempts have been made to compare...

... (BCG), performed in order to reduce the recurrence rate of papillary bladder tumors. As the secretions of the bladder wall are retained in the urine, patients’ urine was collected during 4-hour periods. These urine samples were chromatographed on phosphocellulose. In the elution fractions NAP-1/IL-8...

...Harry W. Herr; Eric A. Klein; André Rogatko Of 221 patients with superficial bladder cancers treated with intravesical BCG, BCG therapy failed locally within the bladder or prostate in 41 patients. A multivariate analysis was done using data on these local failures to identify clinical variables...

...A. Steg; S. Adjiman; B. Debré Bacillus Calmette-Guérin (BCG) immunotherapy represents a valuable treatment in the management of superficial bladder cancer, but the therapy is not without its risks. A total of 220 patients have been included in a review of local and systemic side effects associated...

...D.L. Lamm Immunotherapy provides an effective alternative approach to chemotherapy in the management of superficial bladder cancer. The first widely used immunotherapy, bacillus Calmette-Guérin (BCG), eradicates residual tumour in one half of patients with carcinoma in situ. Unlike chemotherapy...

... selection, treatment protocol, reduction of side effects, mechanisms of action, and thus room enough for laboratory researchers and clinicians to contribute to the improvement of BCG therapy. Initiation of mycobacterial binding to urothelial cells may be promoted by methods which increase fibronectin...

...F. Pagano; P. Bassi; C. Milani; N. Piazza; A. Meneghini; A. Garbeglio Shortly after Morales’ original report, several phase II trials confirmed the effectiveness of intravesical bacillus Calmette-Guérin (BCG) in superficial bladder cancer therapy. Concerns have been expressed about the toxicity...

...A.P.M. van der Meijden Compared to intravesical chemotherapy, instillations with bacillus Calmette-Guérin (BCG) may provoke more frequently local and systemic reactions. As well as irritative bladder symptoms, BCG therapy may cause systemic sideeffects,such as mild malaise, fever and, less commonly...

...H. Akaza There are theoretical limits to the efficacy of intravesical instillation of anticancer agents as a method to prevent recurrence of superficial bladder cancer. Studies on the direct efficacy of intravesical instillation of bacillus Calmette-Guérin (BCG) to treat existing papillary tumours...

... (BCG) could reduce toxicity without compromising efficacy. From February 1991 to June 1992, 500 patients with superficial bladder cancer(TaG2-3, T1G1-3) entered the trial. Of these patients, 252 were included in group A (BCG, 81 mg) and 248 in group B (BCG, 27 mg). There were no significant differences...

.... In contrast, intravesical bacillus Calmette-Guérin (BCG) immunotherapy is effective in high-grade tumours,provides long-term protection from tumour recurrence and reduces disease progression. Controlled clinical trials have consistently demonstrated that BCG provides superior protection from tumour recurrence...

...F. Pagano; P. Bassi; N. Piazza; G. Abatangelo; G.L. Drago Ferrante; C. Milani Several clinical trials have shown intravesical bacillus Calmette-Guérin(BCG) to be effective in the prophylaxis of papillary tumour recurrences and in the therapy of bladder carcinoma in situ (CIS), as well...

... tumour. The question is if this biopsy, in the absence of any visual tumour, should be done. Material and Methods: The ablative effect of MMC, epirubicin, and quarter dose BCG instillations was evaluated in three different studies on a papillary marker lesion. Patients with multiple, primary or recurrent...

...G. Jakse; R. Hall; A. Bono; W. Höltl; P. Carpentier; J.P. Spaander; A.P.M. van der Meijden; R. Sylvester Objectives: This phase II study was designed to assess the response rate, side effects and long–term efficacy of BCG in the treatment of carcinoma in situ (Cis) of the urinary bladder. Methods...

...Bong R. Oh; Koichi Nakajima; Kyu Y. Ahn; Soo B. Ryu; Yang I. Park; Rajvir Dahiya Objective: We hypothesize that Bacille Calmette–Guérin (BCG) may act through the regulation of various isoforms of nitric oxide synthase (NOS) [inducible (iNOS), endothelial (eNOS), and neuronal (nNOS)] genes...

...Alexandre R. Zlotta; Claude C. Schulman Background: For more than 20 years, superficial bladder tumors have been demonstrated to be sensitive to several biological response modifiers and especially to immunomodulators. The best-known and studied immunomodulator is the bacillus Calmette-Guérin (BCG...

...A.R. Zlotta; J.P. van Vooren; K. Huygen; A. Drowart; M. Decock; M. Pirson; F. Jurion; K. Palfliet; O. Denis; J. Simon; C.C. Schulman Objective: For more than 20 years, BCG intravesical therapy schedule has included 6 weekly instillations. Very few studies have, however, analyzed the rationale...

...A. Böhle BCG immunotherapy against superficial bladder carcinoma recurrences is regarded as the most successful to date. However, the mode of action has not yet been fully explained. In this field, several European groups have recently significantly contributed by adding more details to the complex...

...P. Rischmann; F. Desgrandchamps; B. Malavaud; D.K. Chopin Adverse events following intravesical BCG therapy are related to strain virulence, allergic reactions or to nosocomial urinary tract infections. Low grade fever and irritative symptoms are common side-effects of BCG. They subside within 48...